MARC details
000 -LEADER |
fixed length control field |
04651nam a22007217a 4500 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
fixed length control field |
161101s20152015 xxu||||| |||| 00| 0 eng d |
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
International Standard Serial Number |
1050-7256 |
040 ## - CATALOGING SOURCE |
Original cataloging agency |
Ovid MEDLINE(R) |
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
PMID |
26357962 |
245 ## - TITLE STATEMENT |
Title |
Validation of a Simple Thyroid Cancer Dosimetry Model Based on the Fractional Whole-Body Retention at 48 Hours Post-Administration of (131)I. |
251 ## - Source |
Source |
Thyroid. 25(12):1347-50, 2015 Dec. |
252 ## - Abbreviated Source |
Abbreviated source |
Thyroid. 25(12):1347-50, 2015 Dec. |
253 ## - Journal Name |
Journal name |
Thyroid : official journal of the American Thyroid Association |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
-- |
2015 Dec |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
Year |
2015 |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
Manufacturer |
2016 |
266 ## - Date added to catalog |
Date added to catalog |
2017-03-06 |
501 ## - WITH NOTE |
Local holdings |
Available online from MWHC library: August 2000 - present, Available in print through MWHC library: 1999 - 2006 |
520 ## - SUMMARY, ETC. |
Abstract |
BACKGROUND: Standard dosimetric methods to determine the maximum tolerated activity (MTA) of (131)I for the treatment of metastatic, well-differentiated thyroid cancer (DTC) are time-consuming and require complex analysis. As a result, reliable, accurate, and simplified methods are desirable. The objective of this study was to evaluate the validity of a simple regression dosimetry model. |
520 ## - SUMMARY, ETC. |
Abstract |
CONCLUSIONS: The % 48-hour WBR as determined by the bi-exponential function noted herein with reasonable restrictions has been validated as a reliable simplified dosimetry model. |
520 ## - SUMMARY, ETC. |
Abstract |
METHOD: Previously, the authors reported a bi-exponential model for estimating the MTA of (131)I for the treatment of metastatic DTC based on a limit of 2 Gy to the blood. This model uses the patient's body surface area (BSA) along with the fractional whole-body retention (WBR) at 48 hours following oral administration of a diagnostic dosage of (131)I. A bi-exponential regression model was developed between the MTA normalized to the patient's BSA and the percent retention value at the 48-hour time point (R): MTA (GBq)/BSA (m(2))=(13.91 . e(-0.0387R)+ 42.33 . e(-0.8522R)). In this study, the same model was applied to a different set of adult patients referred for dosimetry and possible (131)I treatment of DTC under conditions of thyroid hormone withdrawal or recombinant human thyrotropin (rhTSH) stimulation. All patients (n = 170; 96 female) referred to the authors' clinic for dosimetry and possible (131)I treatment for metastatic DTC during the collection period were included in this study, apart from those undergoing renal dialysis. The MTA predicted (MTAp) using the model described above was compared to the measured MTA (MTAm), with statistical analysis performed using ProStat v4.5. |
520 ## - SUMMARY, ETC. |
Abstract |
RESULTS: In this group, the MTAm ranged from 2.3 to 41.1 GBq. The linear correlation between the MTAp and MTAm was excellent (r = 0.96), with an average deviation of only +/- 1.2%. However, to avoid overdosing a patient on the basis of the MTAp, a weighting factor (<1.0) should be applied (e.g., using a value of 0.7 would result in only one patient receiving a prescribed activity of (131)I that exceeded the MTAm [<3%]). |
546 ## - LANGUAGE NOTE |
Language note |
English |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Carcinoma/rt [Radiotherapy] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Iodine Radioisotopes/tu [Therapeutic Use] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Thyroid Neoplasms/rt [Radiotherapy] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Body Surface Area |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Carcinoma/sc [Secondary] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Female |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Humans |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Linear Models |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Male |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Radiometry |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Radiotherapy Dosage |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Recombinant Proteins |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Regression Analysis |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Reproducibility of Results |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Thyroid Neoplasms/pa [Pathology] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Thyrotropin/tu [Therapeutic Use] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Thyroxine |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Withholding Treatment |
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
Institution |
MedStar Washington Hospital Center |
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
Institution |
MedStar Washington Hospital Center |
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
Institution |
MedStar Washington Hospital Center |
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
Institution |
MedStar Washington Hospital Center |
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
Institution |
MedStar Washington Hospital Center |
656 ## - INDEX TERM--OCCUPATION |
Department |
Medicine/Endocrinology |
656 ## - INDEX TERM--OCCUPATION |
Department |
Medicine/Endocrinology |
656 ## - INDEX TERM--OCCUPATION |
Department |
Medicine/Nuclear Medicine |
656 ## - INDEX TERM--OCCUPATION |
Department |
Medicine/Nuclear Medicine |
656 ## - INDEX TERM--OCCUPATION |
Department |
Medicine/Nuclear Medicine |
657 ## - INDEX TERM--FUNCTION |
Medline publication type |
Journal Article |
657 ## - INDEX TERM--FUNCTION |
Medline publication type |
Research Support, Non-U.S. Gov't |
657 ## - INDEX TERM--FUNCTION |
Medline publication type |
Validation Studies |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Atkins, Francis |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Burman, Kenneth D |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Moreau, Shari |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Van Nostrand, Douglas |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Wartofsky, Leonard |
790 ## - Authors |
All authors |
Atkins F, Burman K, Moreau S, Van Nostrand D, Wartofsky L |
856 ## - ELECTRONIC LOCATION AND ACCESS |
DOI |
<a href="http://dx.doi.org/10.1089/thy.2014.0616">http://dx.doi.org/10.1089/thy.2014.0616</a> |
Public note |
http://dx.doi.org/10.1089/thy.2014.0616 |
942 ## - ADDED ENTRY ELEMENTS (KOHA) |
Koha item type |
Journal Article |
Item type description |
Article |